GSK publishes Q3 2026 results infographic
GSK•GSK reported Q3 2026 sales of £8.9 billion, up 5%, and core operating profit of £3.1 billion, also up 5%. Total earnings per share fell 21% to 38.5p, while core earnings per share rose 1% to 54.6p.
1. Quarterly results
GSK reported Q3 2026 sales of £8.9 billion, up 5%, and core operating profit of £3.1 billion, up 5%. Specialty Medicines sales rose 15% to £3.9 billion, vaccine sales fell 2% to £2.6 billion, and General Medicines sales held steady at £2.4 billion. The dividend was 17p per share.
2. Regulatory approvals
Hibsago secured US and Japanese approvals. US regulators also cleared Jemperli for rectal cancer and Jideytro for lung cancer.
